SLC5A2 and diabetes mellitus: Several clinical trials of the sodium-glucose co-transporter 2 (SGLT2) inhibitors [6] and a meta-analysis [7] have reported that heart failure patients receiving SGLT2 inhibitors had lower risks of cardiovascular death, regardless of the presence [8] or absence of diabetes [9].